May 28, 2026

Following its CE marking, we are seeing strong progress as Valvosoft® enters routine clinical use across Europe. In May, 8 additional patients were successfully treated for calcific aortic stenosis using Valvosoft®, our non-invasive ultrasound therapy developed by Cardiawave.
 
🏥 This continued activity marks an important step in the clinical adoption of Valvosoft®, made possible through close collaboration with leading hospitals.
 
🙏 We warmly thank all clinical teams for their dedication and trust.
 
It is very encouraging to see more patients benefiting from this innovation every week — a clear sign of growing momentum in routine practice.
 
#MedTech #Innovation #Cardiology #PatientCare #HealthcareInnovation
#StructuralHeart #AorticStenosis #Valvosoft #medtech #focusedultrasound #NIUT #TAVI #TAVR #AorticValve #lifetimemanagementofas #valves #CEMarking
 
@AP‑HP, Assistance Publique – Hôpitaux de Paris #HEGP, @Physics for Medicine Paris, #InstitutLangevin, @CNRS, @ESPCI Paris – PSL, @Inserm @RHU_STOP_AS @CHU de Rouen
 
#FrenchCare #Health20 @france-biotech @medicen-paris-region @bpi-france @medtechinfrance @focusedultrasoundfoundation @eic-scalingclub @snitem